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Thymectomy followed by sublethal irradiation was shown to induce autoimmune thyroiditis in rats by Penhale et al. (1975) . Lymphocytic infiltration of the thyroid and production of anti-thyroglobulin lead to destruction of thyroid follicles with a more delayed time course compared with the immunized AUG rat model. IEF spectrotypes of anti-thyroglobulin autoantibodies were much more restricted in the PVG rat model, only one or two clonotypes being present in most cases. This resembles the pattern given by a minor population of Hashimoto's patients (Stott et al., 1986) and may be due to T-cell regulation of the number of responding B-cells (Rose et al., 1981) . Pronounced changes in spectrotype occurred as clonotypes died away and were replaced by new ones, reflecting changes in the response of B-cell clones.
Some clonotypes persisted over the period of the study. giving a maximum lifespan for an autoantibody secreting B-cell clone of at least 16 weeks. (Suzuki et al., 1980) , we have examined the effect of lipocortin 1 binding to human mononuclear cells and neutrophils on the expression of Fc, receptors. Human lipocortin 1 has recently been cloned and expressed (Wallner et al., 1986 ) and the purified recombinant molecule used in these experiments was generously provided by the Biogen Research Corporation (Cambridge, MA, U.S.A.). Mononuclear cells or neutrophils were isolated from the peripheral blood of healthy subjects, washed in calcium-free phosphate-buffered saline to remove endogenous lipocortin and resuspended at a final concentration of 1 x 1 Oh cells/ml in RPMl 1640 medium containing 10% (v/v) fetal bovine serum. Cells were subsequently preincubated for 1 h at 37°C in the presence of increasing amounts of lipocortin (0-30 pg/ml). After a wash step in Dulbecco's minimum essential medium, Fc , receptor expression was assessed. The two methods used were: (a) enumeration of erythrocyte-antibody ( E A ) rosettes formed when leucocytes were incubated at 4°C in the presence of ox erythrocytes sensitized with rabbit anti-(ox erythrocyte)IgG; (b) binding of monoclonal antibodies (mAb) directed against three distinctly characterized Fcy receptors designated type I (mAb 32.2), type 11 (mAb 1V.3) or type 111 (mAb 3G8) (Anderson & Looney, 1986) . rnAb binding was detected by flow cytometry using an indirect staining technique using the F( ab')z fragment of fluorescein isothiocyanate-conjugated anti-mouse IgG. Calibration to enable estimation of the number of Fc, receptors expressed per cell was by the method of Girard et al. ( 1987) .
Abbreviations used: EA, erythrocyte-antibody; mAb, monoclonal antibody.
In a group of four subjects, incubation of mononuclear cells with increasing amounts of lipocortin 1 resulted in a dose-dependent inhibition of E A rosetting with maximum 70% inhibition occurring at 15 pg/ml (Fig. 1 a ) . In a larger group of 12 individuals, incubation of mononuclear cells with this concentration of lipocortin resulted in a decrease in the median number of rosette-positive cells from 18.8 x 1 O4 (range 10.1-30.2 x lo4) to 5.5 x 104 (range 0-14.5 X IO"), representing a significant fall of 70.8% ( I ) < 0.0 1 ) (Fig. 1 b ) . A similar pattern of E A rosette inhibition was found for neutrophils, although maximum impairment of 60% occurred at 30 pg of lipocortin/ml. EA rosette inhibition did not occur when cells were incubated with sham preparations purified from Escherichiu coli which did not contain the gene for human lipocortin. Also, the effect was abrogated when the preincubation step was carried out in calcium-free medium. At a lipocortin concentration of 15 ,ug/ml there was no significant decrease in the expression of Fc, receptors as detected by mAbs directed against any of the three types of receptor on lymphocytes, monocytes or neutrophils (not shown).
In conclusion, this study suggests that lipocortin does not inhibit E A rosetting by a direct effect on receptor expression, but via an action on the mechanisms by which Fc, receptors associate within the membrane to form rosettes. Further studies are in progress to determine whether lipocortin is altering membrane fluidity generally or is binding at or in close proximity to the FCY receptor, thereby affecting its lateral mobility within the plane of the membrane.
IgA is the major immunoglobulin of sero-mucous secretions, where it defends external body surfaces. IgA is also a major serum protein, but in spite of a concentration equivalent to that of IgM or any of the subclasses of IgG, the biological functions of serum 1gA remain unclear. Serum 1gA in man is monomeric, whereas secretory IgA is polymeric containing in addition to IgA, two other proteins, J chain and secretory component. These cover the Fc region of the IgA molecule and therefore would be expected to alter any functions of IgA mediated by this region. Based largely on work with secretory IgA or IgA myelomas of unknown specificity, IgA has generally been assumed to be a poor activator of the complement system and to be unable to opsonize micro-organisms. The role of serum IgA in the inflammatory response is not known.
Serum IgA levels are frequently raised in rheumatic diseases and in other autoimmune diseases as well as in liver disease and persistent infections such as bacterial endocarditis. Elevated IgA levels are associated with rises in serum polymeric IgA and with IgA-containing immune complexes. Immune complexes containing IgA have been suggested to be pathogenic in these and other diseases such as the IgA nephropathies. In rheumatoid arthritis, IgA rheumatoid factor (IgA RF) has been shown to be present in the serum of the majority of patients, with IgA RF secreting lymphocytes being detectable in synovial fluid and at other sites of local inflammation. A strong correlation between raised IgA RF levels at the onset of disease and the eventual severity of the disease, has been reported.
In the past, the possibility that 1gA might be involved in the pathogenicity of immune complex disease has been largely discounted because of its inefficiency in activating complement which was believed to be an important step in the generation of tissue damage. More recently, it has been realized that the activation of complement is in fact an essential step in the solubilization and removal of immune complexes. IgA-containing immune complexes, which activate complement poorly, could be more readily deposited in tissues and therefore be potentially more dangerous.
Abbreviations used: RF. rheumatoid factor; PMN, polymorphonuclear neutrophils.
Recently, we have shown that specific serum IgA antibodies are able to opsonize yeast for phagocytosis by polymorphonuclear neutrophils (PMN) in vitro, suggesting the presence of receptors for IgA on the neutrophil surface. Phagocytosis occurred in the absence of complement proteins and was more rapid than with IgG-opsonized yeasts ( Yeaman & Kerr, 1987) . We have now extended these studies to show that IgA anti-yeast mannan antibodies purified on Jacalin-Sepharose were able to trigger the phagocytosis of the yeast, confirming that IgAl is opsonic for PMN. When phagocytosis assays were carried out in free solution, IgA was far more efficient as an opsonin than IgG, whereas with adherent PMN the two were of similar efficiency. Yeasts opsonized with either IgA or IgG elicited a chemiluminescent burst and caused the degranulation of adherent PMN which could be measured by lysozyme release.
IgA anti-Escherichia coli antibodies isolated from a patient with liver disease and E. coli septicaemia were able t o opsonize E. coli resulting in enzyme release and a chemiluminescent burst, when incubated with normal peripheral blood PMN. The bacteria were clearly phagocytosed when viewed in the electron microscope. In the case of both bacteria and yeasts opsonized with IgA, the chemiluminescent burst elicited from PMN was much more rapid than that elicited by complement-opsonized organisms.
We have also shown that PMN will bind to IgA-Sepharose or IgG-Sepharose, but not bovine serum albumin-Sepharose. Binding to IgA-Sepharose stimulates the cells to release lysozyme. Affinity chromatography of "5-l-labelled PMN membrane proteins on IgA-Sepharose allows the purification of a protein with apparent molecular mass of 60 000 Da, which appears as a single broad band on gels suggesting it is heavily glycosylated. On IgG-Sepharose run undcr identical conditions, IgGFcRl 1 is isolated with a molecular mass of around 40 000 Da.
This first identification of the IgA receptor, confirms and extends previous work from other laboratories which demonstrated the binding of IgA to neutrophils; for example, the work of Henson et a:. (1972) who showed that aggregated IgA myeloma proteins were phagocytosed as efficiently as aggregated IgG. Aggregated IgA also stimulated the release of granule enzymes as potently as IgG immune complexes, both events being mediated by the Fc part of the molecules. Aggregated IgA, but not IgG, has also been shown to inhibit the chemotactic-peptide-mediated migration of PMN. Although this has been suggested to reflect increased adhesiveness or 'activation' of the PMN, the mechanism underlying this process is not known. It is possible that activation of PMN by 1gA-containing immune
